Responses
Regular and young investigator award abstracts
Combination immunotherapies
442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.
